written by reader Stansberry Venture Touts Tiny Biotech Firm About to Explode

By fjoyce1959, March 24, 2015

Dave Lashmet of Stensberry Ventures is out with a new teaser ad about a new clinical phase drug that is being developed by a ting biotech company that will literally change the world. Some of the teaser statements that hint to the company are:
The biotech firm developing this drug is a tiny startup that consists of about 50 employees, most of them scientists. It doesn’t have the resources to produce, market and sell a blockbuster drug on its own.
Lashmet’s announcement concerns the final clinical trial results of a drug so revolutionary, it’s the only one of its kind — and promises to cure a disease that kills more people than HIV and tuberculosis combined.
The drug that Dave Lashmet is touting is one that is designed to fight antibiotic-resistant bacteria.
This disease is caused by a class of pathogens that the Director of the U.S. CDC says could “devastate our economy” and kill millions.
The Phase 2 for this company’s new revolutionary drug showed a 100% success rate and Phase 3 results are expected in 90 Days.
Does this sound familiar to anyone?

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.



This site uses Akismet to reduce spam. Learn how your comment data is processed.

Inline Feedbacks
View all comments
March 24, 2015 5:56 pm

After reading the Tease the company I think he is touting is Tetraphase Pharmaceuticals (TTPH). I would like the opinion of the “Master” to see if I am right!

👍 3